Clinical trial

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

NCT04181788

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention PF-06801591 Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1, PHASE2

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-03-18

PhasePHASE1 / PHASE2

Conditions

Advanced Malignanciesunresolved

Non-small-cell Lung Cancerunresolved

Interventions

PF-06801591DRUG

Sponsors & collaborators

Pfizerlead sponsor

Mapped research locations

Saint PetersburgRussia7 KyivUkraine3 OdesaUkraine3 SeoulSouth Korea2 BeijingBeijing Municipality, China1 ShanghaiShanghai Municipality, China1 TaipeiTaiwan1 NanjingJiangsu, China1 Kaohsiung CityTaiwan1 IncheonSouth Korea1 ChongqingChongqing Municipality, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04181788 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.